{"id":"NCT02405091","sponsor":"Neurocrine Biosciences","briefTitle":"Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia","officialTitle":"A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03","primaryCompletion":"2017-03","completion":"2017-03","firstPosted":"2015-04-01","resultsPosted":"2018-11-30","lastUpdate":"2018-11-30"},"enrollment":167,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Tardive Dyskinesia"],"interventions":[{"type":"DRUG","name":"NBI-98854","otherNames":[]}],"arms":[{"label":"Dose Group 1","type":"EXPERIMENTAL"},{"label":"Dose Group 2","type":"EXPERIMENTAL"}],"summary":"Phase 3, open-label, study to evaluate the safety and tolerability of NBI-98854 administered once daily (qd) for a total of 48 weeks of treatment. This study will enroll approximately 150 medically stable male and female subjects with clinical diagnoses of schizophrenia or schizoaffective disorder with neuroleptic-induced TD or mood disorder with neuroleptic-induced TD.","primaryOutcome":{"measure":"Number of Participants Monitored for Long-Term Safety of Valbenazine","timeFrame":"52 weeks","effectByArm":[{"arm":"Valbenazine 40mg","deltaMin":45,"sd":null},{"arm":"Valbenazine 80mg","deltaMin":107,"sd":null},{"arm":"Valbenazine 80/40mg","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":48,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":["31617235","28839341"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":163},"commonTop":["Urinary tract infection","Headache"]}}